SB 202190: Selective p38 MAPK Inhibitor for Cancer and Inflammation Research

Executive Summary:
SB 202190 (A1632, APExBIO) is a highly selective, cell-permeable inhibitor targeting p38α and p38β mitogen-activated protein kinases (MAPKs) with nanomolar potency (IC₅₀ = 50 nM for p38α, 100 nM for p38β) [product]. The compound operates by competitively binding the ATP-binding pocket, thereby blocking downstream MAPK signaling [internal]. SB 202190 is foundational in studies of apoptosis, inflammatory cytokine modulation, and cancer cell proliferation [bioRxiv]. Its solubility profile (≥22.47 mg/mL in ethanol, ≥57.7 mg/mL in DMSO) and robust performance in cell and animal models have established it as an essential tool for MAPK pathway research [product]. Proper storage and use conditions are critical for assay reproducibility.

Biological Rationale

p38 mitogen-activated protein kinases (MAPKs) are serine/threonine kinases involved in cellular responses to stress, inflammation, and proliferation signals. The p38 MAPK family consists of four isoforms: p38α, p38β, p38γ, and p38δ. p38α and p38β are predominantly expressed in most tissues and are critically involved in regulating pro-inflammatory cytokine production (e.g., TNF-α, IL-6), cell cycle progression, apoptosis, and cellular differentiation [bioRxiv]. Dysregulation of p38 MAPK signaling is implicated in chronic inflammatory diseases, cancer progression, neurodegeneration, and resistance to therapy [internal]. In tumor microenvironments, p38 MAPK activity modulates immune cell differentiation and contributes to immunosuppression by promoting regulatory T cell (Treg) phenotypes [bioRxiv]. Targeting p38α/β is thus strategically important for research into both oncogenic signaling and anti-inflammatory interventions.

Mechanism of Action of SB 202190

SB 202190 is a pyridinyl imidazole compound that acts as a highly selective, ATP-competitive inhibitor of p38α and p38β MAPKs [APExBIO product]. The molecule binds to the ATP-binding pocket of the kinase domain, with a dissociation constant (K_d) of 38 nM for p38α, thereby blocking phosphorylation of both the kinase and its substrates [internal]. SB 202190 does not significantly inhibit other MAPK family members (ERK1/2, JNK) at relevant concentrations, minimizing off-target effects. This selectivity is crucial for dissecting the Raf–MEK–MAPK axis in cell signaling studies. Upon inhibition of p38 MAPK, downstream events such as HSP27 phosphorylation and cytokine production are suppressed, leading to decreased cellular proliferation and increased apoptosis in susceptible cell types [bioRxiv].

Evidence & Benchmarks

• SB 202190 inhibits p38α kinase activity with an IC₅₀ of 50 nM and p38β with an IC₅₀ of 100 nM in biochemical assays (https://www.apexbt.com/sb202190-fhpi.html).
• ATP-competitive inhibition is confirmed by kinetic analyses, with a K_d of 38 nM for p38α at 25°C (https://map-kinase-fragment.com/index.php?g=Wap&m=Article&a=detail&id=19).
• Reduces phosphorylation of HSP27 and ATF2, as well as pro-inflammatory cytokine release, in LPS-stimulated macrophages (https://doi.org/10.1101/2024.07.18.604049).
• Induces apoptosis and suppresses proliferation in colorectal cancer cell lines at 1–10 μM concentrations under standard cell culture conditions (https://doi.org/10.1101/2024.07.18.604049).
• Improves cognitive function and reduces neuronal apoptosis in vascular dementia mouse models when administered intraperitoneally at 2 mg/kg (https://tpca-1.com/index.php?g=Wap&m=Article&a=detail&id=16390).
• Widely used in advanced assembloid and 3D tumor microenvironment models for precise MAPK pathway interrogation (https://ku-0060648.com/index.php?g=Wap&m=Article&a=detail&id=15319).

This article extends prior coverage (e.g., here) by detailing solubility parameters, storage requirements, and recent evidence from organoid-Treg studies for translational relevance.

Applications, Limits & Misconceptions

SB 202190 is a standard MAPK signaling pathway inhibitor for:

• Dissecting the Raf–MEK–MAPK pathway in cancer and inflammation research.
• Assessing apoptosis using flow cytometry and annexin V/PI assays in cell cultures exposed to inflammatory cytokines or chemotherapeutic agents.
• Evaluating p38 MAPK involvement in neurodegenerative and vascular dementia models through behavioral and histological endpoints.
• Interrogating tumor microenvironment interactions in colorectal cancer assembloids and organoid-immune co-cultures [bioRxiv].
• Benchmarking novel kinase inhibitors against a well-characterized, selective reference compound.

For further strategic application, see the guide here, which this article updates by emphasizing solubility, workflow integration, and recent organoid data.

Common Pitfalls or Misconceptions

• SB 202190 is not a pan-MAPK inhibitor; it does not robustly inhibit ERK or JNK at working concentrations.
• Water insolubility requires use of DMSO or ethanol as solvents; aqueous stock solutions are unstable.
• Long-term storage of diluted (solution) forms is not recommended; stability is best ensured by storing the solid at –20°C.
• At concentrations >20 μM, off-target effects or cytotoxicity may occur in sensitive cell lines; dose titration is essential.
• Results in non-mammalian systems or prokaryotes are not validated and should not be generalized.

Workflow Integration & Parameters

For optimal experimental reproducibility, prepare SB 202190 stock solutions at ≥10 mM in DMSO. Solubility is ≥57.7 mg/mL in DMSO and ≥22.47 mg/mL in ethanol. Warm gently to 37°C or sonicate to accelerate dissolution. Working concentrations typically range from 0.1–10 μM in cell-based assays; verify cell line sensitivity prior to use. Final DMSO concentrations in assays should not exceed 0.1% v/v unless otherwise validated. Store solid material at –20°C, protected from light and moisture. Avoid repeated freeze–thaw cycles. Do not store diluted solutions for more than 24 hours at 4°C. For in vivo applications, reference published dosing regimens (e.g., 2 mg/kg intraperitoneal in mouse cognitive models). For further technical integration, see the detailed workflow comparison here, which this article clarifies by directly citing IC₅₀ and K_d data.

Conclusion & Outlook

SB 202190 (A1632, APExBIO) remains the reference selective p38α/β MAPK signaling pathway inhibitor for mechanistic studies in cancer, inflammation, and neurodegeneration. Its nanomolar potency, validated selectivity, and robust solubility parameters streamline its integration across cell and animal models. Recent organoid and assembloid evidence further strengthen its translational value for dissecting immune modulation in tumor microenvironments [bioRxiv]. Ongoing refinements in workflow integration and off-target profiling will further optimize its utility for next-generation research in kinase signaling and therapeutic development.

For detailed product specifications and ordering, see the SB 202190 product page.